Toward Multiparametric MRI to Unravel Myocardial Pathology in Cardiac Amyloidosis.
作者信息
Clerc Olivier F, Jerosch-Herold Michael, Dorbala Sharmila
机构信息
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (O.F.C., S.D.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Amyloidosis Program, Cardiovascular Division, Department of Medicine (O.F.C., M.J.-H., S.D.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
出版信息
Circ Cardiovasc Imaging. 2025 May;18(5):e018178. doi: 10.1161/CIRCIMAGING.125.018178. Epub 2025 May 6.
Abstract
摘要
相似文献
1
Toward Multiparametric MRI to Unravel Myocardial Pathology in Cardiac Amyloidosis.迈向多参数磁共振成像以揭示心脏淀粉样变性中的心肌病理
Circ Cardiovasc Imaging. 2025 May;18(5):e018178. doi: 10.1161/CIRCIMAGING.125.018178. Epub 2025 May 6.
2
[Diagnosing cardiac amyloidosis in magnetic resonance imaging: The discriminating factors].[磁共振成像中诊断心脏淀粉样变性：鉴别因素]
Ann Cardiol Angeiol (Paris). 2020 Nov;69(5):262-267. doi: 10.1016/j.ancard.2020.09.023. Epub 2020 Oct 14.
3
Myocardial extracellular volume quantification in cardiac amyloidosis: a comparative study between cardiac computed tomography and magnetic resonance imaging.心肌细胞外容积在心脏淀粉样变性中的定量评估：心脏 CT 与 MRI 的对比研究。
Eur Radiol. 2024 Feb;34(2):1016-1025. doi: 10.1007/s00330-023-10129-w. Epub 2023 Aug 19.
4
Mechanisms of left ventricular systolic dysfunction in light chain amyloidosis: a multiparametric cardiac MRI study.轻链淀粉样变性中左心室收缩功能障碍的机制：一项多参数心脏磁共振成像研究
Front Cardiovasc Med. 2024 May 30;11:1371810. doi: 10.3389/fcvm.2024.1371810. eCollection 2024.
5
Myocardial Edema and Prognosis in Amyloidosis.心肌水肿与淀粉样变的预后。
J Am Coll Cardiol. 2018 Jun 26;71(25):2919-2931. doi: 10.1016/j.jacc.2018.03.536.
6
MRI-Extracellular Volume Fraction Versus Histological Amyloid Load in Cardiac Amyloidosis: The Importance of T2 Mapping.心脏淀粉样变性中MRI细胞外容积分数与组织学淀粉样蛋白负荷的关系：T2映射的重要性
Circ Cardiovasc Imaging. 2025 May;18(5):e017427. doi: 10.1161/CIRCIMAGING.124.017427. Epub 2025 Mar 21.
7
Myocardial Amyloidosis: The Exemplar Interstitial Disease.心肌淀粉样变性：典型的间质性疾病。
JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 2):2345-2356. doi: 10.1016/j.jcmg.2019.06.023. Epub 2019 Aug 14.
8
Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: T1 Is Not Enough.心脏淀粉样变性中的心血管磁共振成像：仅T1加权成像不够。
J Am Coll Cardiol. 2018 Jun 26;71(25):2932-2934. doi: 10.1016/j.jacc.2018.04.025.
9
Myocardial perfusion in cardiac amyloidosis.心脏淀粉样变的心肌灌注。
Eur J Heart Fail. 2024 Mar;26(3):598-609. doi: 10.1002/ejhf.3137. Epub 2024 Jan 21.
10
State of the Art: Quantitative Cardiac MRI in Cardiac Amyloidosis.技术前沿：心脏淀粉样变的定量心脏 MRI。
J Magn Reson Imaging. 2022 Nov;56(5):1287-1301. doi: 10.1002/jmri.28314. Epub 2022 Jun 30.
本文引用的文献
1
MRI-Extracellular Volume Fraction Versus Histological Amyloid Load in Cardiac Amyloidosis: The Importance of T2 Mapping.心脏淀粉样变性中MRI细胞外容积分数与组织学淀粉样蛋白负荷的关系：T2映射的重要性
Circ Cardiovasc Imaging. 2025 May;18(5):e017427. doi: 10.1161/CIRCIMAGING.124.017427. Epub 2025 Mar 21.
2
Comprehensive prognosis assessment of cardiovascular magnetic resonance parametric mapping in light chain amyloidosis.轻链型淀粉样变中心血管磁共振参数成像的综合预后评估
J Cardiovasc Magn Reson. 2025;27(1):101135. doi: 10.1016/j.jocmr.2024.101135. Epub 2024 Dec 14.
3
Myocardial inflammatory cells in cardiac amyloidosis.心脏淀粉样变性中的心肌炎性细胞。
Sci Rep. 2024 Oct 7;14(1):23313. doi: 10.1038/s41598-024-74289-5.
4
Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis.系统性轻链淀粉样变的心肌特征、心脏结构和心功能。
JACC Cardiovasc Imaging. 2024 Nov;17(11):1271-1286. doi: 10.1016/j.jcmg.2024.05.004. Epub 2024 Jul 10.
5
Parametric mapping using cardiovascular magnetic resonance for the differentiation of light chain amyloidosis and transthyretin-related amyloidosis.应用心血管磁共振进行参数图分析以鉴别轻链淀粉样变性和转甲状腺素蛋白相关淀粉样变性。
Eur Heart J Cardiovasc Imaging. 2024 Sep 30;25(10):1451-1461. doi: 10.1093/ehjci/jeae154.
6
Cardiac MRI T1 and T2 Mapping as a Quantitative Imaging Biomarker in Transthyretin Amyloid Cardiomyopathy.心脏 MRI T1 和 T2 映射作为转甲状腺素蛋白淀粉样心肌病的定量成像生物标志物。
Acad Radiol. 2024 Feb;31(2):514-522. doi: 10.1016/j.acra.2023.08.045. Epub 2023 Sep 27.
7
Cardiac Amyloid Quantification Using I-Evuzamitide (I-P5+14) Versus F-Florbetapir: A Pilot PET/CT Study.使用 I-Evuzamitide（I-P5+14）与 F-Florbetapir 进行心脏淀粉样蛋白定量：一项 PET/CT 研究的初步结果。
JACC Cardiovasc Imaging. 2023 Nov;16(11):1419-1432. doi: 10.1016/j.jcmg.2023.07.007. Epub 2023 Sep 6.
8
Myocardial structural and functional changes in cardiac amyloidosis: insights from a prospective observational patient registry.心脏淀粉样变的心肌结构和功能变化：前瞻性观察性患者注册研究的结果。
Eur Heart J Cardiovasc Imaging. 2023 Dec 21;25(1):95-104. doi: 10.1093/ehjci/jead188.
9
Feasibility of Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis.镓标记成纤维细胞激活蛋白抑制剂 PET/CT 在轻链心脏淀粉样变性中的可行性。
JACC Cardiovasc Imaging. 2022 Nov;15(11):1960-1970. doi: 10.1016/j.jcmg.2022.06.004. Epub 2022 Sep 14.
10
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.心脏磁共振成像在轻链淀粉样变中的应用指导治疗。
Eur Heart J. 2022 Dec 1;43(45):4722-4735. doi: 10.1093/eurheartj/ehac363.
Zotero 插件